Gene -attenuated replication -competent adenoviruses are emerging as a promising new modality for the treatment of cancer. For the aim of improving adenoviral vectors for cancer gene therapy, we have constructed genetically attenuated adenoviral vectors with different combinations of E1B genes and investigated the possibility of enhanced oncolytic and replication effects of these engineered replication -competent adenoviruses. We show here that the cytolytic potency of each gene -attenuated replicating adenovirus differed significantly depending on the presence or deletion of E1B 55 kDa and E1B 19 kDa function. More specifically, among the constructed vectors ( Ad -ÁE1B19, Ad -ÁE1B55, Ad -ÁE1B19 / 55, and Ad -wt ), E1B 19 kDa -inactivated adenovirus ( Ad -ÁE1B19 ) was the most potent against all tumor cells tested, inducing the largest -sized plaques and marked CPE. Further, cells infected with either Ad -ÁE1B19 or E1B19 / 55 kDa -deleted adenovirus ( Ad -ÁE1B19 / 55 ) showed complete cell lysis with disintegrated cellular structure, whereas cells infected with Ad -wt maintained intact cellular and nuclear membrane with properly structured organelles. TUNEL and DNA fragmentation assay also revealed that the Ad -ÁE1B19 or Ad -ÁE1B19 / 55 adenovirus -infected cells showed more profound induction of apoptosis in comparison to wild -type adenovirus -infected cells. The presence of E1B 55 kDa gene was required for efficient viral replication and deletion of E1B 19 kDa function in replicating adenovirus -induced apoptosis, leading to increased cytopathic effects. Moreover, Ad -ÁE1B19 adenovirus showed a better antitumor effect than other E1B -attenuated adenoviruses. Taken together, the replicating adenoviruses deleted in E1B 19 kDa function may serve as an improved vector for anticancer gene therapy in combination with apoptosis -inducing modalities such as chemotherapeutic agents and radiation therapy.
S
elective replication of viral agents in tumors may lead to improved efficacy over nonreplicating agents due to the self -perpetuating nature of viral multiplication, lysis of the infected cancer cell, and secondary infections to adjacent cells. Genetically attenuated adenoviruses are being developed as selectively replicating antitumoral agents, and currently, a number of clinical trials with such viruses are ongoing to treat a variety of cancers. 1 -3 Initial assessment of these trials demonstrates that gene -attenuated adenoviruses have some efficacy and exhibit safety and feasibility of treatment. 2, 4 However, studies have also shown that adenovirus E1B 55 kDa gene deletion conferring selectivity, i.e., deletion of E1B 55 kDa could endow selective replication, frequently results in reduced potency of the virus in tumors. 5, 6 To achieve sufficient antitumor efficacy, geneattenuated replicating adenoviruses are currently being delivered by multiple injections of high -titer virus, 6 or in combination with chemotherapy. 7, 8 Therefore, the development of a novel replication-selective agent with improved potency would be timely and could be applied more widely in anticancer gene therapy.
The E1B region encodes for two major proteins, E1B 19 kDa and E1B 55 kDa. E1B 19 kDa protein is a potent apoptosis inhibitor and a homologue of Bcl -2 -related apoptosis inhibitors. 9 -12 The antiapoptotic effect of Ad E1B 19 kDa was initially described by Rao et al, 13 who observed that E1B 19 kDa inhibited adenovirus E1A protein -induced apoptosis. In several human tumor cell lines, Ad5 E1B 19 kDa was shown to inhibit p53 -induced apoptosis. 14, 15 In addition, the antiapoptotic effect of E1B 19 kDa has been demonstrated to be functionally equivalent to that of Bcl -2 in terms of its ability to inhibit apoptosis induced by growth factor deprivation, treatment with gamma radiation, glucocorticoid, and various cytotoxic drugs. 16 Recently, combination studies with cisplatin or paclitaxel with adenovirus -mediated proapoptotic Bax gene induction have shown a synergistic increase of cytotoxicity against cancer cells. 17, 18 However, adenoviral vectors used in these studies contained intact E1B 19 kDa that can interfere with the antitumor effect by blocking the apoptotic pathway induced by a variety of chemotherapeutic agents. Therefore, the development of E1B 19 kDa gene -attenuated adenovirus could greatly enhance cellular cytotoxicity caused by replicating adenovirus and subsequently could be used alone, or in combination with cytotoxic agents inducing apoptosis -mediated cell death.
Besides interfering with the p53 function during viral infection, E1B 55 kDa protein also performs other functions that are important in viral replication. During the early phase of infection, E1B 55 kDa counteracts E1A functions that would otherwise lead to the stabilization of p53 and the induction of apoptosis. 14 In the late phase, E1B 55 kDa, acting together with the E4 -orf6 gene product, is required for efficient cytoplasmic accumulation and translation of adenoviral mRNA. 19 -21 This is accompanied by shutting off of host mRNA nuclear export and host protein synthesis. Geneattenuated replicating adenovirus, ONYX -015 (originally named dl1520 ), has a deletion in the E1B transcription unit that removes the gene for E1B 55 kDa. This agent has been tested in phases I and II clinical trials for head and neck cancer, pancreatic carcinoma, ovarian cancer, colorectal carcinoma, non small cell lung carcinoma, and oral dysplasias. 2, 3 Despite clear evidence of antitumoral activity in some patients, treatment with ONYX -015 as a single agent has not produced classically defined tumor responses. Thus, although targeting the p53 pathway produces specific cytotoxicity against the p53 mutated cancer cells, the imperfection of the vector system may limit the therapeutic value in in vitro and in in vivo. Previously, we have shown that the E1B 55 kDa -deleted recombinant adenovirus vector ( YKL -1 ) exhibited the tumor-selective replication, but showed reduced cytopathic effect (CPE ) in several tumor cell lines. 22 The reduced potency of dl1520 or YKL -1 may be due to a loss of an important function of E1B 55 kDa that is involved in efficient viral replication such as viral mRNA nuclear transport and accumulation in the cytosol.
Recently, the E1B 19 kDa -deleted adenovirus has been developed, showing increased induction of apoptosis and opening the possibility of enhancing potency of genetically attenuated replicating adenoviruses that can be ultimately used in a clinical setting. 23 In that context, it would be highly desirable to potentiate the cell killing of replicating adenoviruses by enhancing the viral -mediated cell lysis as well as the oncolytic effects of efficient viral replication. Based on these considerations, attempts to engineer E1B 19 kDa and E1B 55 kDa genes have been sought to advance the therapeutic value of replicating adenovirus for cancer gene therapy. However, to date, a systematic comparison and assessment of the therapeutic values of adenoviral E1B 19 kDa and 55 kDa gene -modified adenoviral vectors have not been accomplished. In this study, we have constructed genetically attenuated adenoviral vectors with different combinations of E1B genes and have investigated the possibility of enhanced oncolytic and replication effects of these genetically engineered replicating adenoviruses.
Materials and methods

Cell lines and cell culture
All cell lines, with the exception of Hep3B, were cultured in DMEM supplemented with 10% fetal bovine serum and penicillin -streptomycin ( 100 IU /mL ). The Hep3B cell line was maintained in modified Eagle's medium supplemented with 10% fetal bovine serum and penicillin -streptomycin ( 100 IU /mL ). HEK293 (human embryonic kidney cell line expressing the adenoviral E1 region ), liver cancer cell line ( Hep3B ), lung cancer cell lines (A549 and H460 ), cervical cancer cell line (C33A ), and brain cancer cell line ( U343 ) were purchased from the American Type Culture Collection ( ATCC, Manassas, VA ).
Construction of gene -attenuated adenoviruses
To generate the E1B19 / 55 kDa -deleted recombinant adenovirus (Ad -ÁE1B19 /55 ), the E1A region from nucleotide 343-1657 bp was amplified by polymerase chain reaction ( PCR ) with the following primer set: 5 0 -TTATTGGA-TCCTTTGTCTAGGGCCGCGGG -3 0 as the sense primer and 5
0 -CCAGGATCCAGATCTCCCCATTTAACACGCC-ATGC -3 0 as the antisense primer. The adenoviral shuttle vector, pXC1 (Microbix, Ontario, Canada ), containing the E1 region of adenovirus type 5, was used as a template. The PCR product containing E1A with BamHI site (underlined ) at both 5 0 and 3 0 ends and BglII ( underlined ) at the 3 0 end was digested with BamHI and then subcloned into the BglII site of pCA14 ( Microbix ), generating a pCA14 -E1A shuttle vector. The nucleotide sequence of the amplified PCR product was verified using an ABI PRISM377 automatic DNA sequencer. The pCA14 -E1A shuttle vector was linearized by XmnI digestion. The adenovirus vector vmdl324Bst (obtained from Dr Verca at the University of Fribourgh, Switzerland ) containing the Ad5 genome deleted in the E1 region ( 281-4640 in nucleotide of Ad5 ) and the E3 region (28596 -30470 in nucleotide of Ad5 ) was linearized with BstBI digestion. The linearized pCA14 -E1A was cotransformed into Escherichia coli BJ5183 together with the BstBI-digested vmdl324Bst for homologous recombination. 47 To verify the respective homologous recombinants, the plasmid DNA purified from overnight E. coli culture was digested with HindIII, and the digestion pattern was analyzed. The proper homologous recombinant adenoviral plasmid DNA was digested with PacI and transfected into 293 cells to generate the E1B -deleted adenovirus, Ad -ÁE1B19 /55.
To construct the E1B19 kDa -inactivated adenovirus ( Ad -ÁE1B19 ), pXC1 was digested with XbaI and KpnI, and subsequently subcloned into the XbaI and KpnI sites of pSP72 cloning vector, generating pSP72 /E1B19. Then, the sitedirected mutagenesis ( Stratagene, La Jolla, CA ) in pSP72 / E1B19 was accomplished by PCR amplification using 5 0 -GTTACATCTGACCTCCTGTAGGCTAGCGAGTGTT-TGGAAG -3 0 as the sense primer and 5 0 -CTTCCAAA-CACTCGCTAGCCTACAGGAGGTCAGATGTAAC -3 0 as the antisense primer. The primers were designed to create a stop codon (bold, italicized) and a new NheI site (underlined ) in the region of start codon of E1B 19 kDa. The new NheI site was introduced to confirm the mutation of PCR product. The mutated region was verified using an automatic sequencer. The resulting mutated plasmid pSP72 / ÁE1B19 was digested with XbaI and KpnI, and subcloned into the XbaI and KpnI sites of pXC1. Then, homologous recombination was induced in E. coli BJ5183 with vmdl324Bst as described above. Replication -incompetent adenovirus (Ad-ÁE1), E1B 55 kDa -deleted adenovirus (Ad-ÁE1B55; YKL-1), and wild-type recombinant adenovirus ( Ad -wt ) were also prepared. 22 All viruses were propagated in HEK293 cells and purified according to standard methods. 22 Viruses used in this study are shown in Figure 1 , and Ad -ÁE1 and Ad -wt were used as controls for E1B geneattenuated adenoviruses.
PCR analysis of E1B mutant adenoviruses
U343 cells were infected with Ad -ÁE1, Ad -ÁE1B19 / 55, Ad -ÁE1B19, Ad -ÁE1B55, or Ad -wt at a multiplicity of infection (MOI) of 10. After 2 days postinfection, viral DNA was isolated with a genomic isolation kit (Qiagen, Santa Clarita, CA ). PCR was accomplished using three kinds of E1 region-specific primer sets corresponding to E1A, E1B 19, and E1B 55 kDa, and the expected sizes of PCR products were 479, 429, and 338 bp, respectively. PCR product fragments were then resolved on a 1.8% agarose gel and visualized by UV fluorescence.
Western blot analysis of Ad E1A and E1B 19 kDa protein expression Cells were lysed in 50 mM Tris -HCl (pH 7.6), 1% Nonidet P -40 ( NP -40), 150 mM NaCl, and 0.1 mM zinc acetate in the presence of a protease inhibitors. Protein concentration was determined using the Lowry method (Bio -Rad, Hercules, CA ). Ten micrograms of each sample was separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS -PAGE ). The gels were then electroblotted onto a nitrocellulose membrane. Membranes were blocked in TBST ( 50 mM Tris -HCl, pH 7.6, 150 mM NaCl, 0.2% Tween 20) containing 5% dry milk overnight at 48C. After blocking, membranes were incubated with a rabbit polyclonal IgG against E1A, a mouse monoclonal IgG against E1B 19 kDa, or a mouse monoclonal IgG against E1B 55 kDa (a generous gift from Dr Thomas Dobner in University of Regensburg, Germany ). The secondary antibodies were goat anti -rabbit IgG horseradish peroxidase ( HRP ) or goat anti -mouse IgG HRP. Finally, the blots were developed using enhanced chemiluminescence (ECL ) ( Amersham Pharmacia, Arlington Heights, IL).
CPE assays
To evaluate the CPE, 2 -8Â10 4 cells were plated onto a 24-well plate at about 30 -80% confluence, and then infected with Ad-ÁE1, Ad-ÁE1B19/55, Ad-ÁE1B19, Ad-ÁE1B55, or Ad -wt at an MOI of 0.1 -10. Their killing effect was monitored daily under a microscope. At the moment that cells infected with any one of the virus at an MOI of 0.1 exhibited complete cell lysis, cells on the plate were then stained with 0.5% crystal violet in 50% methanol.
For viral replication assays, cells were grown as described for the CPE assays but were subsequently infected at an MOI of 1 with either E1B mutant or control adenovirus (Ad -ÁE1 or Ad -wt ). Forty -eight hours postinfection, both cells and supernatant were collected for virus titration analysis. Cell lysates underwent three cycles of freezing and thawing, and serial dilutions of supernatants and lysates were tittered on 293 cells.
Electron microscope ( EM ) cytology
A549 cells were infected with Ad -ÁE1B19 or Ad -wt at an MOI of 10. Four days postinfection, cells were gently trypsinized and pelleted for 5 minutes at 3000 rpm in a microcentrifuge tube. After washing with phosphatebuffered saline (PBS ), pellets were fixed for 4 hours at 48C in 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.3) containing 2% sucrose and 1 mM calcium chloride. They were then postfixed with 1% OsO 4 in 0.1 M cacodylate -HCl, pH 7.4, for 1 hour. The samples were dehydrated in a gradient series of ethanol, embedded in Epon812, and examined using an EM.
Virus production assay
To assay for viral growth, cells were plated onto a six -well plate at about 70% confluence, and then infected with Ad -ÁE1, Ad -ÁE1B19 /55, Ad -ÁE1B19, Ad -ÁE1B55, or Ad -wt at an MOI of 1. At various times of incubation at 378C, supernatant and cells were collected and freezethawed three times to release the viruses. Supernatant and monolayer samples were assayed by plaque assay to determine the virus titer.
Plaque development assay
Plaque development assay was carried out on 293, Hep3B, and U343 cell lines as described previously. 48 Briefly, monolayers of each cell line were infected with serial diluted adenoviruses in six -well plates. After 2 hours of incubation Figure 1 Schematic representation of three E1B mutant adenoviruses, Ad -ÁE1B19, Ad -ÁE1B55, and Ad -ÁE1B19 / 55, along with Ad -ÁE1 and Ad -wt. Ad -ÁE1 has the whole E1 region deleted; Ad -ÁE1B19 contains the normal E1A and E1B55 kDa, but is E1B19 kDa translation initiation codon -mutated; Ad -ÁE1B55 contains the normal E1A and E1B19 kDa, but is E1B55 kDa -deleted; Ad -ÁE1B19 / 55 contains E1A, but is E1B19 kDa -and E1B55 kDa -deleted.
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Replicating adenovirus for cancer gene therapy J Kim et al at 378C, the infected cells were overlaid with 4 mL of 0.7% SeaPlaque agarose in DMEM with 5% fetal bovine serum. Following 7-9 days of incubation, agarose overlay was removed after soaking with 10% trichloroacetic acid for 30 minutes, and the remaining cells were stained with 0.5% crystal violet in 50% methanol.
TUNEL assay
Apoptosis was also analyzed by terminal deoxynucleotidyl transferase (TdT )-mediated dUTP nick end labeling ( TUNEL ) assay as described previously. 22 Briefly, A549 cells were plated on a chamber slide 1 day prior to infection, and treated with Ad -ÁE1B19 /55, Ad -ÁE1B19, Ad -ÁE1B55, or Ad -wt at an MOI of 2. After 4 days of infection or treatment with 1 M camptothecin (CPT ), infected cells were rinsed with PBS. Samples were then processed according to the instructions in the ApopTag kit ( Oncor, Gaithersburg, MD ) for the detection of cleaved deoxyribonucleic acid in situ using the TdT-mediated deoxyuridine 5 0 -triphosphate -biotin nick end labeling (TUNEL ) method. The apoptotic cells were counted under magnification (Â400 ) in 10 selected fields. More than 2000 cells were counted to calculate the percentages of TUNEL -positive cells ( apoptotic cell ratio ).
DNA fragmentation assay
Confluent cultures were treated with CPT at 1 M or infected with Ad -ÁE1, Ad -ÁE1B19, Ad -ÁE1B55, Ad -ÁE1B19 / 55, or Ad -wt at an MOI of 10. Cells were harvested and suspended in a lysis buffer ( 10 mM Tris -HCl, pH 8.0, 100 mM NaCl, 25 mM EDTA, 0.5% SDS, and 100 g/mL Proteinase K ) for 20 hours at 378C. DNA was extracted with a mixture of phenol and chloroform, precipitated by ethanol, dried, and dissolved in a TE buffer. DNA samples were analyzed by electrophoresis on a 2% agarose gel containing ethidium bromide ( 0.5 g/mL ) and then visualized under a UV illuminator.
Antitumor effect of E1B mutant adenoviruses in vivo
The antitumor effect of the following viruses was tested in vivo: Ad-ÁE1, Ad -ÁE1B19, Ad -ÁE1B55, Ad -ÁE1B19 / 55, and Ad -wt. Five -to 6 -week -old female nude mice were purchased from Charles River (Yokohama, Japan ). Tumors were implanted on the abdomen of each animal by subcutaneous injection of 10 7 tumor cells in 100 L of PBS. Tumor growth was monitored on a 2-to 3-day interval by measuring the length and width of the tumor with a caliper. Tumor volume was calculated using the following formula: volume= 0.523Lw 2 . When tumors reached a range of 60 -70 mm 3 , animals were randomized into five groups of six animals each. First day of treatment was designated as day 1. Adenoviruses were administered intratumorally ( 5Â10 8 PFU per tumor in 50 L of PBS ) on days 1, 3, and 5. Tumor growth delay was assessed by taking measurements on a 2-to 3 -day interval. When the tumors reached the maximum acceptable size, mice were sacrificed and their tumors were excised and analyzed histologically (hematoxylin and eosin ). Tumor responses to each treatment were compared by Mann -Whitney test.
Results
Generation and characterization of E1B mutant adenoviruses
To characterize and compare the E1B mutant adenoviruses' potential for cell killing effect, three E1B -attenuated adenoviruses ( Ad -ÁE1B19, Ad -ÁE1B55, and Ad -ÁE1B19 /55 ) were developed as described in Materials and Methods. First, Ad -ÁE1B19 was designed to be deficient of the E1B 19 kDa protein by inserting a stop codon in the region of E1B 19 kDa translation initiation codon. Second, Ad -ÁE1B55, as described previously, lacked the E1B 55 kDa gene. 22 Finally, Ad -ÁE1B19 /55 was designed to express neither the E1B 19 kDa nor the 55 kDa proteins due to the deletion of both genes. All three constructs were created in adenovirus subtype 5 dl324 background ( Fig 1 ) . The E1 region -specific primer sets corresponding to E1A, E1B19 kDa, and E1B55 kDa are shown below the diagram of E1 region of adenovirus genome, and each expected size of PCR products is 479, 429, and 338 bp, respectively. B: PCR product analysis of E1B mutant adenoviruses. Left marker ( GIBCO, Gaithersburg, MD ), 1 -kb DNA ladder. The presence of each PCR product verified the presence of the gene deletion. C: Detection of the E1A, E1B 19 kDa, and E1B 55 kDa protein by Western blot analysis. Twentyfour hours after infection, total protein from A549 cells infected with Ad -ÁE1, Ad -ÁE1B19, Ad -ÁE1B55, Ad -ÁE1B19 / 55, or Ad -wt at a dose of 10 MOI was analyzed with anti -E1A, anti -E1B19, or anti -E1B55 antibody as described in Materials and methods.
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Gene constructs of each generated adenoviruses were verified by PCR using appropriate primer sets amplifying each E1 region corresponding to E1A, E1B 19 kDa, and E1B 55 kDa genes (Fig 2A ) . The U343 brain tumor cell line was infected with each E1B mutant adenovirus at an MOI of 10 along with Ad -ÁE1 and Ad -wt as a negative and a positive control, respectively. After 2 days postinfection, viral DNA was isolated and subsequently used for PCR amplification using three E1 -specific primer sets. As expected with the E1A -specific primer set, PCR generated the DNA fragment of 489 bp from all samples except Ad -ÁE1 -infected U343 cells ( Fig 2B ) . Deletion of E1B 55 kDa gene in Ad -ÁE1B55 genome was confirmed by PCR amplification using E1B 55 kDa -specific primer set, resulting in no PCR product of 338 bp. However, E1A ( 479 bp ) and E1B 19 kDa ( 429 bp ) DNA fragments were amplified with E1A -and E1B 19 kDa -specific primers, respectively, indicating that Ad -ÁE1B55 had a deletion of E1B 55 kDa gene but that the E1A and E1B 19 kDa regions were still intact in the genome. The Ad -ÁE1B19 / 55 genome structure was verified by PCR amplification, generating only a E1A -specific PCR product ( 479 bp ) but not E1B 19 kDa and E1B 55 kDa products. This result indicated that E1B 19 kDa and E1B 55 kDa genes were properly deleted in Ad -ÁE1B19 /55 genome. When Ad -ÁE1B19 -infected U343 cell-derived genomic DNA was amplified by three E1 region -specific primer sets, three products corresponding to E1A, E1B 19 kDa, and E1B 55 kDa were obtained. Ad -ÁE1B19 genome, which only has a change of an initiation codon at the stop codon but retained all coding sequences of E1B 19 kDa region, resulted in amplification of all three PCR -amplified DNA fragments.
To verify the gene composition of the three E1B mutant adenoviruses, E1A, E1B 19 kDa, and E1B 55 kDa protein expressions were evaluated by immunoblotting with anti -E1A, anti -E1B 19 kDa, anti -E1B 55 kDa antibodies. As shown in Figure 2C , no expression of E1B 19 kDa was found in cell lysates derived from cells infected with Ad -ÁE1B19 or Ad -ÁE1B19 /55 adenoviruses in contrast to those infected with Ad -ÁE1B55 or Ad -wt adenoviruses. The expression of E1B 55 kDa was detected in cells infected with Ad -ÁE1B19 or Ad -wt in contrast to those infected with Ad -ÁE1B55 or Ad -ÁE1B19 /55. Next, as expected, E1A protein was well expressed in cells infected with each E1B -attenuated adenovirus or wild -type adenovirus but not with Ad -ÁE1 adenovirus. These results confirmed that, as intended, all three E1B mutant adenoviruses possessed proper E1B gene organization and expression pattern.
Evaluation of cell killing effect of E1B mutant adenoviruses
To quantitatively assess adenovirus replication-dependent cell killing effects, cell cytotoxicity of each mutant adenovirus was analyzed by an in vitro CPE assay. Cells were grown to 50-80% confluence and then infected at an MOI of 0.1-10. For control, cells were infected in parallel 
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Replicating adenovirus for cancer gene therapy J Kim et al with nonreplicating adenovirus Ad -ÁE1 and wild -type adenovirus. As shown in Figure 3 , Ad -ÁE1B19 exerted marked CPE against all tumor cell lines tested. The cell lysis capacity of Ad -ÁE1B19 was about 10-100 times greater than either Ad -ÁE1B55 or Ad -ÁE1B19 / 55, and about 5-20 times greater than wild adenovirus Ad -wt. At similar MOIs, the decrease in viable cells was significantly more evident in cells infected with Ad -ÁE1B19 than in those with any other E1B mutant adenoviruses. These results demonstrated that the loss of E1B 19 kDa enhanced adenoviral lytic potency over that of other E1B mutant adenoviruses as well as that of wild type. In regards to comparison of Ad -ÁE1B19 /55 to Ad -ÁE1B55 adenovirus, Ad -ÁE1B19 / 55 adenovirus exerted higher potency of cell killing over Ad -ÁE1B55 adenovirus. More specifically, Ad -ÁE1B19 / 55 showed about 20 times greater cytotoxicity than Ad -ÁE1B55 adenovirus in A549 cells, and about 2-5 times greater potency in C33A, H460, Hep3B, U251N, and U343 cells. Overall, these four replication -competent adenoviruses exerted varied CPE in the order of Ad -ÁE1B19>Ad -wt>Ad -ÁE1B19 / 55>Ad -ÁE1B55.
Different rates of cell death were also observed morphologically. U343 cells infected with Ad -ÁE1, Ad -ÁE1B19, Ad -ÁE1B55, Ad -ÁE1B19 / 55, or Ad -wt adenovirus at an MOI of 10 were observed by light microscope up to 7 days. Ad -ÁE1 adenovirus -infected cells showed no CPE during the observed time course. Cells infected with Ad -ÁE1B19 exhibited obvious CPE and cell lysis by 2 days postinfection, whereas cells infected with other Ad E1B mutants or with Ad -wt were nearly all intact until 3 days postinfection, and cell death progressed from days 4 to 7. A representative example of these cells at 4 days postinfection is shown in Figure 4 . Cell death process by infection with Ad -ÁE1B19 was faster than that of any other adenoviruses.
It has been noted that cells infected with E1B 19 kDaattenuated adenoviruses, Ad -ÁE1B19 and Ad -ÁE1B19 /55, showed distinct morphology in the CPE in that the cell membrane was almost completely lysed and cellular structure was severely disintegrated (Fig 4 ) . In comparison, cells infected with Ad -ÁE1B55 or Ad -wt showed typical adenovirus -mediated cell lysis, having cells rounded up and detached from the plastic dishes into floating cells and forming grape -like clusters. The floating cells were highly light-refractive and majority of these cells were viable as judged by viability studies using trypan blue exclusion assay.
The morphological difference observed was further examined by EM. At 4 days postinfection at an MOI of 10, majority of A549 cells infected with Ad -ÁE1B19 adenovirus were lysed, whereas nearly all Ad -wt -infected cells were intact. The nuclei in the Ad -wt -infected cells were extremely swollen, occupying nearly the entire cell ( Fig 5A ) . Nuclei were packed with viruses but the nuclear membrane still appeared to be intact. In some cells, crystals of viruses were observed ( Fig 5D ) . All intracellular organelles in Ad -wt -infected cells were intact and retained proper structure. However, cells infected with Ad -ÁE1B19 were completely lysed. The cellular membrane and nuclear membranes were severely disintegrated and not distinct ( Fig 5B ) . The intracellular organelles were also hardly distinguished, and some showed ballooning degeneration. Viral particles were observed to spread out in the cytoplasm. 
U343
Days post infection Days post infection Virus titer (pfu/ml)
Ad-∆ E1 Ad-∆ E1B19/55
Ad-∆ E1B19 Ad-∆ E1B55 Ad-wt Figure 6 Virus production assay. Monolayers of 293 and U343 cells were infected with Ad -ÁE1, Ad -ÁE1B19 / 55, Ad -ÁE1B19, Ad -ÁE155, or Ad -wt at an MOI of 1. The virus present in cell and supernatant was extracted at the indicated days postinfection, and titers were determined by plaque assay.
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These ultramicroscopic features favor necrosis rather than apoptosis in that the cells do not exhibit the typical features of apoptosis, i.e., cell shrinkage, membrane blebbing, and membrane -bound apoptotic bodies. However, one of major characteristics of apoptosis, chromosome condensation, was observed in Ad -ÁE1B19 adenovirus -infected cells ( Fig 5E ) . Therefore, it appears that the Ad -ÁE1B19 infection seems to have the capability of inducing both apoptosis as well as cellular necrosis in the same cells. Recent reports on murine polyomavirus infection showed specifically that the infected cells do undergo both apoptosis and necrosis, with cellular necrosis being the predominant event. Other viruses such as Newcastle disease virus, 24 human herpesvirus 7, 25 and infectious pancreatic necrosis virus 26 have also been shown to induce both apoptosis and necrosis in the same cell.
Ad -ÁE1B19 replicates as efficiently as wild -type adenovirus
Premature cell lysis by induction of apoptosis may lead to early viral release, possibly resulting in reduction of total production of viral progeny. Such a loss of viral production may reduce the efficacy of virotherapy for cancer treatment. Therefore, the effect of deletion of E1B 19 kDa or presence of E1B 55 kDa on viral production was examined. To examine and compare viral replication of each E1B mutant versus wild -type adenovirus, cells were infected with a specific adenovirus at an MOI of 1. Then the accumulation of viral particles in culture medium and cell fraction was determined by a plaque assay. As shown in Figure 6 , total viral yields of Ad -ÁE1B19 and Ad -wt were similar in U343 cells, reaching a plateau after 5 days postinfection (Fig 6A ) . Ad -ÁE1B55 and Ad -ÁE1B19 / 55 virus yields did not reach a plateau until 8 days postinfection, and the total yield of virus was less than those of Ad -ÁE1B19 and Ad -wt. These results indicate that E1B 55 kDa -containing adenoviruses, Ad -ÁE1B19 and Ad -wt, replicate very actively, whereas E1B 55 kDa -deleted adenoviruses, Ad -ÁE1B55 and Ad -ÁE1B19 /55, replicate less efficiently in the panel of cancer cells tested. However, the loss of E1B 19 kDa function did not affect viral replication. Therefore, the efficient replication of adenovirus depends on the presence of E1B 55 kDa, but not on the E1B 19 kDa gene.
Ad -ÁE1B 19 adenovirus induced biggest plaques
Replication and viral spread from cell to cell was visualized in a plaque development assay. Monolayers of 293, Hep3B, and U343 cell lines were infected with five different adenoviruses, and plaque formation was monitored. Figure 7 shows a representative plaque assay with Ad -ÁE1, Ad -ÁE1B19, and Ad -wt. The size of plaques formed by Ad -ÁE1B19 was larger than that of Ad -wt, and more numbers of plaques were observed in Hep3B and U343 cells. However, all three adenoviruses ( Ad -ÁE1, Ad -ÁE1B19, and Ad -wt ) developed the same number and size of plaques in the 293 cells, which complement the E1 gene in trans. The number of plaques formed in the Hep3B cells infected with E1B mutant adenoviruses was counted at 3, 5, and 8 days 
Ad-E1B19
Ad-wt Ad-∆ E1 U343 ∆ Figure 7 Plaque morphology of Ad -ÁE1, Ad -ÁE1B19, and Ad -wt on 293, Hep3B, and U343 cells. After a 2 -hour adsorption period, plates were overlaid with agarose and incubated. At 7 -9 days postinfection, the agarose overlay was removed, stained with crystal violet, then photographed. Ad -ÁE1B19 lacking E1B 19 kDa mutant adenovirus developed larger and more number of plaques than Adwt. Nonreplicating adenovirus Ad -ÁE1 did not develop any plaque except on E1 complementing cell line 293. Figure 8 Plaque development assay for E1B -attenuated adenoviruses. Hep3B cells were infected with Ad -ÁE1, Ad -ÁE1B19 / 55, Ad -ÁE1B19, Ad -ÁE155, or Ad -wt. After 2 hours of adsorption period, plates were overlaid with agarose and incubated. After 3, 5, and 8 days postinfection, the agarose overlay was removed. The cells were then stained with crystal violet and counted. The plaques of Ad -ÁE1B19 and Ad -wt developed much faster than other E1B mutant adenoviruses, Ad -ÁE1B19 / 55 and Ad -ÁE155, but the final titers obtained for all virus stocks were similar.
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Replicating adenovirus for cancer gene therapy J Kim et al after infection, and plotted in Figure 8 . Consistent with results in Figure 7 , Ad -ÁE1B19 showed enhanced plaque development when compared to other E1B mutants or wildtype adenovirus. With Ad -ÁE1B19, 92 plaques were observed at 8 days postinfection vs 78, 25, and 17 plaques for Ad -wt, Ad -ÁE1B55, and Ad -ÁE1B19 / 55, respectively (Fig 8B ) . Therefore, the rate of plaque development by infection with Ad -ÁE1B19 was faster than any other E1B mutant adenoviruses tested in this study, including the wild -type adenovirus. However, the other E1B 19 kDaattenuated adenovirus, Ad -ÁE1B19 / 55, developed plaques slowly and formed less number of plaques than Ad -wt, similar to Ad -ÁE1B55 (Fig 8B ) . Thus, Ad -ÁE1B19 / 55
and Ad -ÁE1B55 were not as effective as Ad -ÁE1B19 in promoting cell lysis, not only in CPE assay but also in the plaque development assay.
Cellular apoptosis is enhanced in the E1B 19 kDa -attenuated adenovirus -infected cells
To examine whether the attenuation of E1B 19 kDa function could affect the cell death pathway, DNA integrity was monitored after viral infection. TUNEL and DNA fragmentation assays were used to evaluate the induction of apoptosis and tumor cell killing. A549 cells, infected with Ad -ÁE1, Ad -ÁE1B19, Ad -ÁE1B55, Ad -ÁE1B19 / 55, or Ad -wt at an MOI of 2, were evaluated for induction of apoptosis by TUNEL assay after 4 days postinfection. CPT ( 1 M) was used as a positive control to induce apoptosis. Infection with Ad -ÁE1B19 induced the most potent apoptosis, showing that approximately 46.7% of the nuclei had a nicked DNA, whereas apoptosis induced by Ad -wt was nearly undetectable ( 4.3% ) (Fig 9 ) . The mean percentage of apoptotic cells induced by each adenovirus is summarized in Table 1 . Ad -ÁE1B19 /55 induced apoptosis in about 20% of the infected cells, whereas Ad -ÁE1B55 induced apoptosis at a very low rate (6.0% ). Thus, DNA is degraded much faster in cells infected with Ad -ÁE1B19 or Ad -ÁE1B19 /55 than in those infected with Ad -wt or Ad -ÁE1B55. These DNA breaks have been studied in more detail. The formation of DNA fragments consisting of multimers of approximately 180 bp has been regarded as a hallmark of apoptosis. 27 
Suppression of growth of established tumors by the E1B mutant adenoviruses
We subsequently assessed the relative antitumor efficacy of E1B mutant adenoviruses in a human xenograft model ( human hepatoma cell line, Hep3B, implanted in nude mice). When the subcutaneously implanted tumors reached 5 mm in diameter, tumors were injected intratumorally with Ad -ÁE1, Ad -ÁE1B19, Ad -ÁE1B55, Ad -ÁE1B19 / 55, or Ad -wt at a dose of 5Â10 8 PFU per animal every 2 days for a total of three times. In tumors derived from the Hep3B cells, treatment with A549 cells were infected with Ad -ÁE1B19, Ad -ÁE1B55, Ad -ÁE1B19 / 55, or Ad -wt at an MOI of 10. Cells were harvested on day 4 after infection. The TUNEL assay was performed as described in Materials and methods. The number of brown stained cells per 100 cells was counted. Each of the indicated values reflects the mean of three independent experiments, and is expressed as the percentage of apoptotic cells.
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Replicating adenovirus for cancer gene therapy J Kim et al the replicating adenoviruses significantly suppressed tumor growth when compared with control adenovirus, Ad -ÁE1. Control tumors grew very rapidly, with a greater than 33 -fold increase in size by day 31 ( day 1, 77.5 ± 39 mm 3 ; day 31, 2541 ± 592 mm 3 ), whereas E1B -attenuated adenoviruses significantly suppressed the growth of Hep3B tumors (Ad -ÁE1B19, %ÁT/ ÁC =2; Ad-ÁE1B55, %ÁT /ÁC = 21; Ad -ÁE1B19 /55, %ÁT/ ÁC =8, P <.05 ) ( Fig 11 ) . By day 10, Ad -ÁE1B19 -treated tumors showed a %ÁT/ ÁC of À 11 ( negative number signifies partial regression ), with total tumor regression in one of the six mice tested. Ad -ÁE1B55 -and Ad -ÁE1B19 /55 -treated tumors showed %ÁT / ÁC of 5 and À 6, respectively, at this time period. The mouse showing regression has been followed for over 2 months without evidence of tumor regrowth. Similar results were obtained in the C33A tumor model with the subcutaneous injection of 1Â10 7 C33A cells in nude mice (data not shown ). Two animals from each treatment group were euthanized 7 days after the three sequential treatments, and the tumors were harvested for histological examination. Hematoxylin -eosin staining revealed that after infection with Ad -ÁE1B19, Ad -ÁE1B55, Ad -ÁE1B19 /55, or Ad -wt, the remaining tumor mass consisted largely of necrotic tissue.
Minimal toxicity after intratumoral delivery of the replicating adenoviruses
To evaluate the replicating adenoviruses -related toxicity after intratumoral injection, histopathological changes in liver, kidney, and lung were examined for the two mice from each experimental group that were euthanized 7 days following three sequential intratumoral adenovirus administrations. No lesions were found in the liver, kidney, and lung in all animals examined ( data not shown). To further document the toxicity by the replicating adenovirus treatment, blood samples were collected from animals 5 days after the last of the three sequential intratumoral treatments. Serum levels of liver enzymes, GOT, GPT, ALP, T-bili, and ALB were normal, and no significant differences were found among groups Table 2 . Together, these results indicated that the intratumoral injection of replicating adenovirus is safe and well tolerated in mice and thus could be a promising approach for cancer therapy in humans. Blood was collected from animals 5 days after the last of the three sequential intratumoral treatments. Serum levels of liver enzymes, GOT, GPT, ALP, T-bili, and ALB were normal, and no significant differences were found among groups.
Discussion
The importance of E1B 55 kDa gene involved in p53 inactivation has been studied extensively. Similar activity has been reported for the E4 -ORF6 protein. Like E1B 55 kDa, E4 -ORF6 binds p53 and antagonizes p53 -mediated transactivation. 28, 29 The E4 -ORF6 and E1B 55 kDa proteins also regulate the function of p53 by affecting its half -life. 30 -32 These functions of E1B 55 kDa protein for p53 inactivation enabled the engineering of E1B 55 kDa -deleted adenovirus for oncolytic adenovirus specific to p53 mutant cancer cells. Additionally, the E1B 55 kDa protein performs other important functions involved in viral replication. Late in adenovirus infection, large amounts of viral mRNA are accumulated in the cytosol, whereas cellular mRNA transport and translation are decreased. 19 Forming a physical and functional complex with E4 -ORF6, the E1B 55 kDa product mediates the accumulation of viral mRNA and inhibits the host cellular mRNA transport and translation. 20,33 -35 Therefore, the loss of E1B 55 kDa function endows tumorselective replication and cell lysis, but this may compromise the efficiency of viral replication. To translate this work to a clinical application, this imperfection of the vector system could limit the therapeutic effect for cancer treatment.
The requirement of E1B 55 kDa for efficient viral replication was also demonstrated in our study. In viral replication assay, only the Ad -ÁE1B19 adenovirus containing the E1B 55 kDa replicated as efficiently as the wild type among the three E1B -attenuated adenoviruses. The other two mutant E1B 55 kDa -deleted adenoviruses, Ad -ÁE1B55 and Ad -ÁE1B19 /55, showed reduced viral replication in comparison to wild -type adenovirus. These lines of evidence demonstrate that E1B 55 kDa gene is required in replicating adenoviral gene construct for efficient viral replication, which is critical for the therapeutic value of replicating adenovirus for cancer gene therapy.
In a CPE assay, the E1B 19 kDa -inactivated adenovirus expressing E1B 55 kDa had a greater ability to lyse cells than the E1B 55 kDa -deleted counterpart Ad -ÁE1B19 /55 and Ad -ÁE1B55 or the wild type. The other E1B 19 kDaattenuated mutant adenovirus, Ad -ÁE1B19 /55, also showed more potent cell killing effect (about 5-50 times higher ) than Ad -ÁE1B55. These findings support the conclusion that the deletion of antiapoptotic protein E1B 19 kDa increased the rate of cell lysis. Sauthoff et al 23 previously reported that deletion of the E1B 19 kDa gene may enhance the cytolytic effects of a replicating adenoviral vector, which is consistent with our results.
In respect to plaques morphology, the size of plaques formed by Ad -ÁE1B19 was larger than that of Ad -wt. Consistent with this, the total number of plaques appeared at an earlier postinfection period by Ad -ÁE1B19 infection and was higher than that of Ad -wt. However, Ad -ÁE1B19 / 55 did not form plaques as fast as Ad -ÁE1B19, even though both constructs have deletions of the E1B 19 kDa protein.
Formation of plaques is a net result of viral replication in the cells and the release of virus from infected cells. Thus, a possible explanation of how the E1B 19 kDa -attenuated adenovirus, Ad -ÁE1B19, developed larger and more numbers of plaques than Ad -wt is either that they replicated more efficiently than wild -type Ad or that the progeny virions were released faster. From the result of viral replication assay (Fig 6) , it was revealed that Ad -ÁE1B19 replicated at the same rate as that of wild -type adenovirus. Therefore, its more probable that the deletion of E1B 19 kDa accelerated the efficient lysis of Ad -infected cells, resulting in Ad -ÁE1B19 forming the largest plaques that were faster to develop.
For the elucidation of the underlying mechanism responsible for the rapid cell killing of Ad -ÁE1B19 adenovirus, several assays detecting apoptosis were employed. The active induction of apoptosis by Ad -ÁE1B19 and Ad -ÁE1B19 /55 adenoviruses was demonstrated by TUNEL and DNA fragmentation assay, and efficient cell lysis was shown by plaque -forming assay. These findings are in accordance with earlier studies in that infection with the E1B 19 kDa mutant adenovirus caused the induction of cellular and viral DNA degradation and enhanced CPEs. 36 -39 In support of these results, the E1B 19 kDa protein has a wellestablished function of interfering with E1A -induced apoptosis, preventing premature death of the host cells. 40, 41 In addition, the E1B 19 kDa protein has been shown to inhibit the cytotoxic action of tumor necrosis factor a ( TNF -a) or anti -Fas antibodies, both of which induce apoptosis. 42, 43 Taken together, these results indicate that the deletion of the E1B 19 kDa gene in replicating adenovirus induces E1A -mediated apoptosis as well as direct viral cytolysis, all of which ultimately lead to increased CPEs, rapid viral release, improved cell-to -cell spread, active induction of apoptosis, and efficient viral replication.
In recent clinical trials, tumor-selective replicating viruses were examined to assess its potential in enhancing the effect of known chemotherapeutic agents, cisplatin or 5 -fluorouracil. 7, 8 Results showed that the combination of tumor-selective replicating virus and either of these agents yielded a significantly better efficacy over treatment with chemotherapeutic agent alone. TNF -a 44 and adenovirus death protein ( ADP ) 45 have also been shown to enhance the efficacy of replicating adenoviruses. The E1B 55 kDa genedeleted replicating adenovirus, ONYX015, is currently in phase II clinical trial, being assessed for its ability to enhance the effect of cisplatin or 5 -fluorouracil. 2, 3 However, to date, all the replicating adenoviruses used in combination studies still retain the E1B 19 kDa gene, which, as mentioned before, is a strong antiapoptotic agent. Because cell death induced by many chemotherapeutic agents is mainly driven by the apoptotic pathway, the E1B 19 kDa gene may interfere with the mode of action of these agents, underestimating the value of these combination studies.
Our results confirmed previous reports that the deletion of E1B 19 kDa function enhanced the cytolytic effect. 23 Moreover, Ad -ÁE1B19 adenovirus showed potent antitumor effect, suggesting that E1A -mediated apoptosis may be involved in addition to direct viral -induced cytolysis. The suppression of apoptosis by E1B 19 kDa was also demonstrated by earlier reports in which the investigators reported that the E1B 19 kDa protein efficiently prevents cisplatin -induced apoptosis. 46 Taken together, the replicating adenoviruses deleted in E1B 19 kDa function may serve as an improved vector for anticancer gene therapy in combination with other apoptosis -inducing modalities such as chemotherapeutic agents and radiation therapy.
